10x Genomics, Inc. (TXG) - Comprehensive Stock Analysis & Investment Research
Deep dive into 10x Genomics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.
10x Genomics, Inc. Investment Summary
When evaluating whether 10x Genomics, Inc. (TXG) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.
Company Profile
10x Genomics, Inc. (TXG) operates within the Industrial Applications and Services sector, specifically in the Laboratory Analytical Instruments industry. The company employs approximately 500 people. With a market capitalization of $3 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.
Financial Performance Analysis
Our comprehensive financial analysis covers 10x Genomics, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...
AI Price Predictions
Get AI-powered 7-day, 30-day and 90-day price forecasts for 10x Genomics, Inc. along with confidence scores and detailed analysis...
Investment Considerations
Expert analysis of whether 10x Genomics, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...
Corporate Identity
10x Genomics, Inc. (Stock Symbol: TXG) is a prominent company operating within the Industrial Applications and Services sector, with a specific focus on the Laboratory Analytical Instruments industry. The company's shares are publicly traded on the Nasdaq exchange.
Leadership & Workforce
Detailed information about 10x Genomics, Inc.'s leadership team, workforce size, and organizational structure...
Market Classification
Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for 10x Genomics, Inc....
Sector & Industry Analysis
In-depth sector dynamics and industry context for 10x Genomics, Inc....
Revenue & Growth Analysis
10x Genomics, Inc. generates annual revenues of $642 million , representing an emerging company in its growth phase.
Profitability Metrics
Net profit margin, gross margin, and operating margin analysis for 10x Genomics, Inc....
Market Valuation
P/E ratio, price-to-book, and valuation multiples for 10x Genomics, Inc....
Return Metrics
Return on equity (ROE), return on assets (ROA), and capital efficiency for 10x Genomics, Inc....
Strategic Market Position
10x Genomics, Inc. strategically competes in the highly dynamic Laboratory Analytical Instruments marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.
Industry Competitive Landscape
10x Genomics, Inc. competes within the Industrial Applications and Services sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.
Operational Efficiency
The company currently shows negative free cash flow of $-129 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.
Margin & Pricing Power Analysis
The company maintains a 583.1% gross margin which reflects exceptional pricing power and/or an asset-light business model. Gross margins at this level are typically seen in software, pharmaceuticals, or luxury goods companies where the cost of incremental production is minimal relative to selling prices. Such margins indicate significant competitive advantages protecting the company from price-based competition.
Operating margin of -278.0% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. Operating margin compression relative to gross margin suggests high operating expenses that may warrant efficiency improvements or reflect necessary growth investments.
Asset Utilization Efficiency
Asset turnover ratio of 0.51x indicates moderate asset turnover common in capital-intensive industries such as utilities, real estate, or heavy manufacturing. Lower turnover in these sectors is expected due to the significant infrastructure required for operations.
Financial Strength & Leverage
Current ratio of 7.38 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.